

Nordic Urothelial Cancer Group

Report for the NUF meeting 2015



The tradition is that the group meets once a year in March and once more biannually in conjunction with the NUF Congress. Representatives from all the Nordic Countries, except Iceland, have participated for the last several years.

During the last year, the group has co-chaired the third Nordic Course on Radical Cystectomy and Urinary Diversion together with the reconstruction group. The course took place at Rigshospitalet in Copenhagen November 2014 and included 4 different live surgeries. Broadcasts of the lectures are available for streaming at www.nuf.nu

At the last meeting (March 2015 in Sigtuna), there was an update on the biomarker studies based on samples from patients participating in the previous Nordic Trials on neoadjuvant chemotherapy, CIS and T1-tumors. The group discussed the next theoretical steps regarding biomarkers in bladder cancer. If a very convincing marker is found, first step will be validation in a large-scale observational multi-center study to prove reproducibility and then finally an intervention study to prove the potential clinical impact.

The most recent update from the Nordic CIS trial interestingly showed that practically no recurrences were seen more than ten years after study inclusion. The few that *did* recur after this time, died despite the follow-up regimen. Thus, indications are given that lifelong control is not clinically relevant even in this high-risk group.

The preliminary work with a Nordic cystectomy database (NorCyD) has been initiated. Because of the current regulations, a running prospective database is not warranted but a research focus on neoadjuvant regimens and complications during and after chemo will be the focus. The group found it relevant also to include patients scheduled for neoadj chemo not coming for cystectomy because of side effects

Interestingly, many studies on new drugs for metastatic BC are up and running in the Nordic countries owing to a very active oncological group, the NUCOG. The urological Urothelial Cancer Group will have a closer cooperation with this group in the future.

Per-Uno Malmström has announced his resignation as chairman of the group and will be replaced by Jørgen Bjerggaard Jensen, Aarhus, Denmark following the NUF congress in Malmö.



Jørgen Bjerggaard Jensen
Secretary